OpenEvidence nabs $250 million, doubles to $12 billion valuation as medical AI heats up
OpenEvidence raised $250 million in a Series D round co-led by Thrive Capital and DST Global, doubling its valuation to $12 billion in three months. The medical AI startup says over 40% of U.S. physicians use its tool daily. The company plans to use the new funds for research, development, and expanding its AI system. Most revenue comes from advertising, with the platform free for clinicians with a National Provider Identifier.